Researchers at the Texas A&M University Naresh K. Vashisht College of Medicine (TX, USA), under the leadership of Ashok Shetty,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Terray’s TerraBind Delivers 26x Faster Inference and Enhanced Accuracy, Challenging Diffusion-Based AI Models in Drug Discovery
In a significant development poised to reshape the landscape of AI-driven drug discovery, Terray Therapeutics, a Los Angeles-based startup, has…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, recently announced compelling Phase 2 trial results for its investigational…
Read More
Terray says TerraBind delivers 26x faster inference than Boltz-2 by skipping diffusion-based coordinate generation
Terray Therapeutics, a burgeoning startup based in the Los Angeles area, has unveiled TerraBind, a groundbreaking potency prediction model designed…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Terray says TerraBind delivers 26x faster inference than Boltz-2 by skipping diffusion-based coordinate generation
In a significant development for AI-driven drug discovery, Terray Therapeutics, a Los Angeles-area startup, has introduced TerraBind, a novel potency…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
